CA9 and lung cancer: Conjugation of anti‐carbonic anhydrase IX (CA IX) antibodies to the surface of liposomes improved tumor targeting, as CA IX is a hypoxia‐inducible enzyme, overexpressed in many cancers with a hypoxic TME,130 although antibodies against CA IX alone have not shown significant improvement in lung cancer outcomes.131